---
title: "Weekly Recap | Beigene +2.35%, closing in on record highs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305537085.md"
description: "Beigene (ONC) added 2.35% this week to close at $416.54, about 0.16 percentage points behind the S&P 500. The stock opened at $410 on Monday and hit the week’s high of $424.73 on Tuesday. Monday through Wednesday saw a steady climb, Thursday pulled back to $415.96, and Friday closed slightly higher at $416.54. The weekly range was 3.64%, with average daily volume of 468,300 shares, roughly a third above the 60-day median."
datetime: "2026-11-14T06:52:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305537085.md)
  - [en](https://longbridge.com/en/news/305537085.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305537085.md)
generator: "portal-rs"
---

# Weekly Recap | Beigene +2.35%, closing in on record highs

## The Week

Beigene (ONC) added 2.35% this week to close at $416.54, about 0.16 percentage points behind the S&P 500. The stock opened at $410 on Monday and hit the week’s high of $424.73 on Tuesday. Monday through Wednesday saw a steady climb, Thursday pulled back to $415.96, and Friday closed slightly higher at $416.54. The weekly range was 3.64%, with average daily volume of 468,300 shares, roughly a third above the 60-day median.

## Key Events

The week’s news centred on two themes: continued positive sell-side reactions to the third-quarter results, and a new drug being considered for priority review. On Monday, Citi raised its target to $507. On Tuesday, CLSA and Daiwa followed with higher targets, with Daiwa citing another earnings beat and raised full-year guidance. On Wednesday, a drug candidate moved towards priority review, and the stock hit a record high in premarket trading. Technical notes on Monday highlighted a golden cross and renewed focus on valuation. Company-specific product updates and the earnings trajectory were the dominant narrative for the week.

## Analyst Ratings

Among the 27 firms covering the stock, 19 rate it buy, 7 rate it overweight, and 1 rates it hold, meaning 26 of 27 give a buy or overweight rating. The consensus rating is strong buy, with a consensus target of $469.23, about 12.65% above the latest price. Individual targets range from $400 to $561.30, a fairly wide spread. The stock ranks 11th among 514 companies in the biotechnology industry.

## The Week Ahead

Macro data dominates next week. US retail sales, retail sales ex-autos, import prices, industrial production, and the NAHB housing market index are all due on Tuesday, while the New York Fed manufacturing index lands on Monday. On the company side, no earnings are scheduled for next week; the next known report is the fiscal 2026 annual results due on 25 March 2027.

## In Short

Analyst positioning is heavily skewed towards buy or overweight, and the consensus target sits more than 12% above spot, but the wide target range signals real disagreement. On the latest trading day, large-lot flow was tilted towards selling. Fundamental events and ratings lean positive, while the latest flow data point the other way. What matters next is how macro data shifts risk appetite, and whether large-lot flow turns back towards buying.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)

## Related News & Research

- [BeOne Medicines: Five solid-tumor programs advance as strong cash flow funds continued pipeline investment](https://longbridge.com/en/news/305810947.md)
- [Why BeOne Medicines Stock Is In Focus After Earnings Beat And Raised Guidance](https://longbridge.com/en/news/304730912.md)
- [BeOne Medicines (ONC) Priority Review And Earnings Put Valuation Back In Focus](https://longbridge.com/en/news/304861942.md)
- [BeOne stock breaks out with visions of 177% earnings growth. This telltale clue bodes well.](https://longbridge.com/en/news/302773305.md)
- [Is ServiceNow (NOW) Trading At Too High A Premium For Earnings?](https://longbridge.com/en/news/306039339.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**